comprehensive -WSS

comprehensive

author：focus 2025-09-28 23:51:55 - browse：15874

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： AstraZeneca loses challenge to Medicare drug price negotiation

WSS

House looks to weaken Medicare negotiation

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

ALS groups 'won't be played again' by the FDA, drug sponsors

FDA does about

FDA's Pazdur wants cancer trials to range beyond China alone

Congress gives doctors Medicare pay bump

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Trump demands the U.S. pay no more for drugs than other countries … again

Kaiser's Risant Health gobbled up Geisinger. Who is next?

What does generative AI mean for health care? We asked experts

Obesity now affects over 1 billion people worldwide, study finds

23andMe had bad news about my health. I wish a person had delivered it

Scientists unlock the key to scar

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Wikipedia

Obesity now affects over 1 billion people worldwide, study finds

RSV vaccines may be linked to small increased risk of developing GBS

Clinical trials giant ICON acquires HumanFirst

Why getting cancer drugs just got harder for rural patients

The Pandemic Treaty must support building strong health systems

FogPharma raises $145 million in rare Series E round

focus

knowledge

leisure time

explore